Research-use catalog page
COA request, lot visibility, availability, and schema stay aligned.
IGF-1 LR3 is an 83-amino-acid IGF-1 analog with reduced IGFBP binding, extending half-life from ~15 minutes to ~20–30 hours — the most studied long-acting IGF-1 analog in preclinical research.
Temporarily unavailable
This product is listed in the catalog, but it is not currently available for ordering. Pricing, specifications, and support details remain visible while launch availability is being finalized.
Free shipping on orders over $150
Research Supplies
Need bacteriostatic water, syringes, or an alcohol prep kit? Email us — we can bundle reconstitution supplies with your order.
Ask about a research kit →Need the COA before you order? Request it here.
In your order
Lyophilized vial
Sterile-filtered, freeze-dried peptide in glass vial, sealed under inert gas.
Lot ID on every vial
Printed lot ID ties this exact vial to its analytical record.
COA on request
Independent third-party HPLC certificate, matched to your lot, sent on request.
Carrier-tracked shipping
Shipped from a US facility with full carrier tracking and protective packaging.
The Peptific standard
Peptide quality is invisible until it isn’t. Lot identity, purity, fill integrity, and chain of custody are the difference between usable research material and wasted budget.
Third-party HPLC tested
Every lot is tested for identity and purity by an independent analytical lab. Certificate of Analysis available on request, tied to the exact lot you receive.
Lyophilized and lot-tracked
Sterile-filtered, freeze-dried, sealed under inert gas. Each vial carries its own lot ID — full chain of custody from fill to delivery.
US-based fulfillment
Orders ship from a temperature-controlled US facility with carrier tracking. No drop-shipping, no opaque overseas relay.
Real support, not a ticket queue
A real person responds to research questions, lot questions, and order questions — usually same business day. No bot triage.
How it works
IGF-1 LR3 binds IGF-1 receptors with comparable affinity to native IGF-1 but with dramatically reduced binding to IGF-binding proteins (IGFBPs), prolonging its effective half-life in vivo. Receptor engagement activates the PI3K/Akt/mTOR pathway, stimulating muscle protein synthesis and satellite cell activation in preclinical models. The LR3 modification is the critical pharmacokinetic distinction from native IGF-1.
Compound profile
Product definition
IGF-1 LR3 is an 83-amino-acid IGF-1 analog with reduced IGFBP binding, extending half-life from ~15 minutes to ~20–30 hours — the most studied long-acting IGF-1 analog in preclinical research.
IGF-1 Long R3 is a modified form of human IGF-1 developed to circumvent the binding protein problem that limits native IGF-1's utility in research and therapeutic contexts. The modification involves substitution of glutamate with arginine at position 3 and addition of a 13-amino-acid extension to the N-terminus, together producing a molecule with <1% of native IGF-1's IGFBP-3 binding affinity. In preclinical research, IGF-1 LR3 is investigated for its role in muscle protein synthesis, satellite cell activation, myotube hypertrophy, glucose transporter expression in skeletal muscle, and anabolic signaling through PI3K/Akt/mTOR. The extended half-life relative to native IGF-1 makes it significantly more practical for animal studies examining sustained IGF-1 receptor engagement.
Research audience
IGF-1 LR3 is used by researchers in muscle biology, sports science preclinical work, metabolic signaling, GH-IGF axis research, and anabolic pathway pharmacology. It is the standard long-acting IGF-1 analog used when extended receptor engagement is required for a study protocol.
Research context
IGF-1 LR3 was developed as a research tool to extend the effective window of IGF-1 receptor engagement beyond what native IGF-1 allows due to rapid IGFBP sequestration. The compound is manufactured by multiple research suppliers and has been used across hundreds of published preclinical studies examining anabolic signaling and metabolism. In muscle biology research, IGF-1 LR3 is studied for its effects on satellite cell proliferation and differentiation — key events in skeletal muscle repair and hypertrophy. In cell culture systems, it produces robust PI3K/Akt/mTOR activation at nanomolar concentrations, making it a standard tool for signaling pathway studies. In in vivo rodent studies, it has been used to examine body composition effects, muscle mass responses, and metabolic parameters. The compound also shows binding to the insulin receptor, though with approximately 11% of native insulin's potency. This cross-reactivity is relevant for metabolic research designs and should be considered when interpreting in vivo results.
Common questions
Research Use Only
Sold for laboratory and research purposes only. Not approved for, nor intended for, human or veterinary consumption, diagnostic use, or therapeutic application. These products have not been evaluated by the Food and Drug Administration. Keep out of reach of children. For use by qualified researchers only.
Nothing on this page constitutes medical advice, a treatment recommendation, or a clinical protocol. Consult a qualified healthcare provider before making any health or treatment decisions.
By accessing this product page you confirm that you are a qualified researcher aged 18 or older and that you will use this product solely for lawful laboratory research purposes. View Research Use Policy
You might also want to check out these products.
2X Blend CJC-1295 Without DAC / Ipamorelin
The 2X Blend combines CJC-1295 Without DAC and Ipamorelin — the standard GHRH+GHRP research combination producing synergistic, selective GH pulse amplification through two independent receptor systems.
CJC-1295 Without DAC
CJC-1295 Without DAC (MOD GRF 1-29) is a tetrasubstituted GHRH(1-29) analog with ~30-minute half-life — the preferred short-acting GHRH analog for pulsatile GH research protocols, commonly paired with ipamorelin.
CJC-1295 With DAC
CJC-1295 With DAC is a long-acting GHRH analog with albumin-binding modification that sustains elevated GH and IGF-1 for 6–8 days per administration in preclinical and early clinical research.
GHRP-6 Acetate
GHRP-6 is a hexapeptide GHS-R1a agonist and the founding GHRP compound — studied in preclinical models for GH release, significant appetite stimulation, and cortisol co-stimulation via ghrelin receptor activation.
Ipamorelin
Ipamorelin is a selective pentapeptide GHRP studied in preclinical models for GH release without cortisol or prolactin elevation — the most selective GHRP in its class.
Hexarelin Acetate
Hexarelin (Examorelin) is the most potent characterized GHRP hexapeptide — GHS-R1a agonist with Phase II human data and unique CD36 cardiac receptor binding providing GH-independent cardioprotection in animal models.
IGF-DES
Tesamorelin
Tesamorelin is a 44-amino-acid GHRH analog with N-terminal trans-3-hexenoic acid modification — the only FDA-approved GHRH peptide, validated in Phase III trials for visceral adiposity reduction.
Sermorelin
Sermorelin is a 29-amino-acid synthetic GHRH(1-29) analog — the first FDA-approved GHRH peptide (Geref), with the longest published research history of any synthetic GHRH compound.
MOD GRF 1-29
MOD GRF 1-29 (CJC-1295 Without DAC) is a tetrasubstituted GHRH(1-29) analog with ~30-minute half-life — the most commonly used short-acting GHRH compound for pulsatile GH secretion research.
GHRP-2
GHRP-2 (Pralmorelin) is a synthetic hexapeptide GHS-R1a agonist approved in Japan for GH stimulation testing — a potent non-selective GHRP that stimulates GH alongside cortisol and prolactin.
$25.00
$12.00
$29.00